TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
about
Adoptive T-cell therapy for LeukemiaThe roles of hyaluronan/RHAMM/CD44 and their respective interactions along the insidious pathways of fibrosarcoma progressionBioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.Molecular characterization of T cell receptor beta variable in the peripheral blood T cell repertoire in subjects with active tuberculosis or latent tuberculosis infection.Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.Survivin-specific T cell receptor targets tumor but not T cells.Transgelin-2 in B-Cells Controls T-Cell Activation by Stabilizing T Cell - B Cell Conjugates.Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.Is it time to abandon RHAMM/HMMR as a candidate antigen for immunotherapy of acute myeloid leukemia?RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity.Can immunotherapy specifically target acute myeloid leukemic stem cells?Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment.Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.Cellular immunotherapy strategies for Ewing sarcoma.New approaches for the immunotherapy of acute myeloid leukemia.The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cellsA CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.The progress and current status of immunotherapy in acute myeloid leukemia.Advances in immunotherapy for pediatric acute myeloid leukemia.Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
P2860
Q27006934-CAC392C9-BAA2-46B0-9AA7-2A48B299435BQ27025313-E69B8EC2-5D27-44A3-9363-9DDD674021D6Q33729728-BFB65FC5-3C5F-4BCF-919F-24D6745A84B3Q34980349-0F872F22-4379-4D16-B173-4EB96E21392CQ35196739-7CE7005B-924F-4F8C-AE1D-357E398DB2D1Q35242576-9779CCBA-3E27-48E4-900F-B832CEE0CC05Q36032528-C46A724E-4F35-427F-AE60-59159F54D131Q36173272-E97765E0-AF39-4797-957D-988B8B7A582DQ36366928-A5BC0B3F-D919-4D75-B91D-9175DCCE4F91Q36366953-704F80A4-96D2-4282-933A-9A1BF7CFA92FQ36643631-5AA5AE14-2ECF-4778-9150-A6DA5CBCE1A6Q36694901-E8DC20DD-F732-4E94-84DE-0127EA2A4A55Q37323038-C091708E-6448-4270-AD0E-3C7CBD0BB8A8Q38066860-35BF3945-9CAF-415F-8E19-BE7AFDF26620Q38217594-D4E158EB-E3A0-409D-88B6-A9B4938D879FQ38482206-C506D181-90C7-4453-9FC1-B26797DD7E75Q39360428-840EE93B-3372-4846-A6EF-94A92E6B0791Q41961217-E2792133-D899-4314-9E5B-CE893B5A08DDQ47143616-AFF168C1-C2A2-4DEA-866F-1E3585F91536Q47590707-1E6E838E-EE87-4BD4-83FA-EBCA287F6BAAQ47930962-B23A4691-4A1B-46C4-93D7-4104BBB629D4Q50708752-660438EF-8A04-4852-B6EE-905187AA38BE
P2860
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
@en
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
@nl
type
label
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
@en
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
@nl
prefLabel
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
@en
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
@nl
P2093
P1433
P1476
TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo
@en
P2093
Barbara Mosetter
Bernhard Frankenberger
Dolores J Schendel
Lilian Stärck
Matthias Leisegang
Mirjam H M Heemskerk
Stefani Spranger
Susanne Wilde
Wolfgang Uckert
P304
P356
10.1182/BLOOD-2011-06-357939
P407
P577
2012-02-27T00:00:00Z